Life Science Software 2013: Markets And Opportunities
NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Biopharm Reports has carried out six studies in the life science field, which examined the use of specialist software and databases relating to the conduct of PCR, DNA sequencing, DNA microarray, flow cytometry, mass spectrometry and disease biomarker studies. These studies, which involved the participation of more than 2200 end-users in 70 countries, were carried out to assist software developers and vendors to identify market opportunities in these fields.Techniques such as PCR, DNA microarray, DNA sequencing, mass spectrometry and flow cytometry have seen significant growth over the last decade and by 2015, markets for these five areas are expected to exceed $50 billion, globally. However, none of these developments would have been possible without parallel developments in computing and software. Together they provide the systems that allow the high volumes of complex information that these technologies generate, to be handled. Scientific and clinical needs have driven the development of a multitude of data handling, software, databases and bioinformatics platforms. But, despite the many products available, end-users are often restricted in what they can do due to software limitations. Markets are also changing, which demand new software solutions.Biopharm Reports has published a new report on the use of software and databases in the life science field. This is the outcome of six global studies involving more than 2,200 end-users in the PCR, DNA microarray, DNA sequencing, mass spectrometry, flow cytometry and disease biomarker fields. These finding provide substantial information on end-user practices and opportunities in these markets. This Report Provides: • Software and Databases: A breakdown of end-user practices in the use of software and databases (including software/database market brands or in-house) in the conduct of PCR, DNA microarray, DNA sequencing, mass spectrometry, flow cytometry and disease biomarker studies.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts